3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
5
Terminated
2
Recruiting
2
Active not recruiting
2
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
18
Thoracic
10
Head & Neck
8
Lymphoid
4
CNS
4
Other hematologic neoplasm
3
Genitourinary
2
Sarcoma
1
Other
1
Gynecologic
1
Conditions
Ovarian Neoplasms
1423
Uterine Cervical Neoplasms
926
Endometrial Neoplasms
493
Carcinoma, Ovarian Epithelial
426
Breast Neoplasms
425
Fallopian Tube Neoplasms
413
Neoplasms
274
Uterine Cervical Dysplasia
208
Colorectal Neoplasms
170
Carcinoma, Non-Small-Cell Lung
168
Pancreatic Neoplasms
156
Prostatic Neoplasms
153
Lung Neoplasms
151
Stomach Neoplasms
126
Peritoneal Neoplasms
119
Sarcoma
117
Uterine Neoplasms
112
Melanoma
111
Urinary Bladder Neoplasms
108
Papillomavirus Infections
107
Colonic Neoplasms
106
Head and Neck Neoplasms
105
Vulvar Neoplasms
101
Esophageal Neoplasms
100
Recurrence
95
Testicular Neoplasms
91
Carcinoma, Renal Cell
89
Vaginal Neoplasms
79
Small Cell Lung Carcinoma
77
Kidney Neoplasms
74
Interventions
3-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Hypoxia
×
Gynecologic
×
Clear all
NCT01075399
2013-08-30
HX4-200
Siemens Molecular Imaging
Phase 2
Completed
50 enrolled
7 charts